Projects & Grants

Internal Grant Competition DGC
START-UP grant

Stability of Pentraxin 3 in bronchoalveolar lavage and blood serum samples
Project IdSGS08/LF/2023
Main solverMgr. Radim Dobiáš, Ph.D.
Period1/2023 - 12/2023
ProviderSpecifický VŠ výzkum
AnotationAspergillus fumigatus is the most clinically significant member of the Aspergillus genus, and it is currently classified as a fungal pathogen with a high priority for diagnosis and therapy by the WHO. Due to its small size, the spore penetrates deep into the human respiratory system and, under certain conditions, can cause a wide range of clinical problems. Starting with hypersensitivity pneumonia to the most serious form, which is invasive aspergillosis. This can occur due to primary hypersensitivity, immunodeficiency based on oncological diseases and their therapy, severe respiratory infections (H1N1, COVID19, bacterial infections), long-term antibiotic treatment and massive corticosteroid therapy. In the bronchoalveolar lavage fluid (BALF) samples, significantly high concentrations of the acute phase protein Pentraxin 3 (Ptx3) can be quite advantageous in the diagnosis of invasive fungal diseases (IFD), according to the findings of an observational retrospective study conducted as part of the SGS01/LF/2021 and SGS05/LF/2022 projects. The stability of Pentraxin 3 is an important question that has not yet been answered. This is a basal criterion that will be useful, particularly in the context of future clinical studies, in better defining the versatility of Ptx3 as a reliable biomarker of IFD. The aim of this study is to evaluate the stability of the Ptx3 in BALF and blood serum samples over time and different storage temperatures. In the course of five measurement points, over five months, the concentration values of Ptx3 in the stored clinical samples will be determined. Statistically significant changes of the Ptx3 concentration in the BALF and blood serum samples will be evaluated over time and during different storage temperatures. The obtained data will be analysed to supplement current knowledge about Ptx3, to clarify the question of the stability of this biomarker, and to clarify the possibilities of incorporating the Ptx3 test in clinical practice.